Potentiation of antitumor immunity by antibody-directed enzyme prodrug therapy

International Journal of Cancer

Volumn 94, Issue 6, 2001, Pages 850-858

  Chen, Bing Mae ^a   Cheng, Tian Lu ^a   Tzou, Shey Cherng ^a   Roffler, Steve R ^a  

^a INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

Author keywords

ADEPT; Hepatocellular carcinoma; Immunoenzyme; Immunotherapy; Prodrug

Indexed keywords

4 AMINOPHENOL; BETA GLUCURONIDASE; CD4 ANTIGEN; CD8 ANTIGEN; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DIRECTED ENZYME PRODRUG THERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASCITES CELL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; HELPER CELL; LIVER CELL CARCINOMA; LYMPHOCYTE DEPLETION; MACROPHAGE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; RAT; SUPPRESSOR CELL; TUMOR IMMUNITY;

ANILINE MUSTARD; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CYTOSINE DEAMINASE; GLUCURONIDASE; LIVER NEOPLASMS, EXPERIMENTAL; NUCLEOSIDE DEAMINASES; PRODRUGS; RATS; RATS, SPRAGUE-DAWLEY; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0035892310     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.1550     Document Type: Article

References (56)

1. A cytotoxic agent can be generated selectively at cancer sites
2. Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate
3. Intratumoral generation of 5-fluorouracil mediated by an antibody-cytosine deaminase conjugate in combination with 5-fluorocytosine
4. Bystander killing of tumour cells by antibody-targeted enzymatic activation of a glucuronide prodrug
5. Regressions and cures of melanoma xenografts following treatment with monoclonal antibody beta-lactamase conjugates in combination with anticancer prodrugs
6. Antibody directed enzyme prodrug therapy (ADEPT): Clinical report
7. Antibody directed enzyme prodrug therapy (ADEPT): A review of the experimental and clinical considerations
8. Anti-neoplastic glucuronide prodrug treatment of human tumor cells targeted with a monoclonal antibody-enzyme conjugate
9. Poly(ethylene glycol) modification of beta-glucuronidase-antibody conjugates for solid-tumor therapy by targeted activation of glucuronide prodrugs
10. Establishment of a transplantable ascites variant of a rat hepatoma induced by 3′-methyl-4-dimethylaminoazobenzene
11. Potentiation of radioimmunotherapy by inhibition of topoisomerase I
12. Cure of malignant ascites and generation of protective immunity by monoclonal antibody-targeted activation of a glucuronide prodrug in rats
13. Specific activation of glucuronide prodrugs by antibody-targeted enzyme conjugates for cancer therapy
14. MRC OX-19: A monoclonal antibody that labels rat T lymphocytes and augments in vitro proliferative responses
15. In vivo treatment with monoclonal antibody 3.2.3 selectively eliminates natural killer cells in rats
16. Molecular nature of the W3/25 and MRC OX-8 marker antigens for rat T lymphocytes: Comparisons with mouse and human antigens
17. The JAM test. A simple assay for DNA fragmentation and cell death
18. Prevention of diabetes in BioBreeding/Worcester rats with monoclonal antibodies that recognize T lymphocytes or natural killer cells
19. Alkylating agents prodrugs for ADEPT
20. Cells lacking CIP1/WAF1 genes exhibit preferential sensitivity to cisplatin and nitrogen mustard
21. Cross-resistance and glutathione-S-transferase-pi levels among four human melanoma cell lines selected for alkylating agent resistance
22. Hypoxia-selective antitumor agents. 3. Relationships between structure and cytotoxicity against cultured tumor cells for substituted N,N-bis(2-chloroethyl)anilines
23. Hematopoietic toxicity and cell cycle perturbations induced by new DNA minor groove-alkylating agents
24. Clinical evaluation of two weekly dose schedules of 'IC-140'. 4-N, N-bis (2-chloroethyl) amino phenyl N (P-carboxyphenyl) carbamate, in the treatment of solid tumors
25. Immunization with haptenized, autologous tumor cells induces inflammation of human melanoma metastases
26. Role of host antigen receptor-bearing and antigen receptor-negative cells in immune response to rat adenocarcinoma 13762
27. Adhesion of tumoricidal eosinophils to MCA-38 colon adenocarcinoma cells involves protein tyrosine kinase activation and is diminished by elevated cyclic AMP in the effector cell
28. Cancer gene therapy with HSV-tk/GCV system depends on T-cell-mediated immune responses and causes apoptotic death of tumor cells in vivo
29. Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component
30. Generation of an anti-tumour immune response in a nonimmunogenic tumour: HSVtk killing in vivo stimulates a mononuclear cell infiltrate and a Th1-like profile of intratumoural cytokine expression
31. Herpes simplex virus thymidine kinase/ganciclovir-mediated killing of tumor cell induces tumor-specific cytotoxic T cells in mice
32. 5-Fluorocytosine-induced eradication of murine adenocarcinomas engineered to express the cytosine deaminase suicide gene requires host immune competence and leaves an efficient memory
33. Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression
34. The immune response elicited by mammary adenocarcinoma cells transduced with interferon-gamma and cytosine deaminase genes cures lung metastases by parental cells
35. Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild type tumor
36. Characterization of an antineoplastic glucuronide prodrug
37. Induction of potent antitumor natural killer cell activity by herpes simplex virus-thymidine kinase and ganciclovir therapy in an orthotopic mouse model of prostate cancer
38. Cytosine deaminase/5-fluorocytosine-based vaccination against liver tumors: Evidence of distant bystander effect
39. Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors
40. Ganciclovir chemoablation of herpes thymidine kinase suicide gene-modified tumors produces tumor necrosis and induces systemic immune responses
41. Characterization of the antitumor immune response generated by treatment of murine tumors with recombinant adenoviruses expressing HSVtk, IL-2, IL-6 or B7-1
42. Adenovirus-mediated combined suicide gene and interleukin-2 gene therapy for the treatment of established tumor and induction of antitumor immunity
43. Combination gene therapy for liver metastasis of colon carcinoma in vivo
44. Local and systemic antitumor response after combined therapy of mouse metastatic tumors with tumor cells expressing IFN-alpha and HSVtk: Perspectives for the generation of cancer vaccines
45. Status of radiolabeled monoclonal antibodies for diagnosis and therapy of cancer
46. Perceptions of Herceptin: A monoclonal antibody for the treatment of breast cancer
47. Overview of the clinical development of rituximab: First monoclonal antibody approved for the treatment of lymphoma
48. Clinical trials of antibody therapy
49. Bystander effect in herpes simplex virus-thymidine kinase/ganciclovir cancer gene therapy: Role of gap-junctional intercellular communication
50. Adenovirus-mediated GM-CSF gene and cytosine deaminase gene transfer followed by 5-fluorocytosine administration elicit more potent antitumor response in tumor-bearing mice
51. Immunocytokines: A promising approach to cancer immunotherapy
52. Effect of cyclosporine on immunogenicity of a bacterial enzyme carboxypeptidase G2 in ADEPT
53. Molecular and functional characterisation of a fusion protein suited for tumour specific prodrug activation
54. Construction and characterization of a fusion protein of single-chain anti-CD20 antibody and human beta-glucuronidase for antibody-directed enzyme prodrug therapy
55. Improved characteristics of a human beta-glucuronidase-antibody conjugate after deglycosylation for use in antibody-directed enzyme prodrug therapy
56. Toward antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1 and novel in vivo stable prodrugs of methotrexate